Akèy › Kansè nan tete › Utah › Salt Lake City
Etid klinik pou Kansè nan tete nan Salt Lake City, UT
27 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Salt Lake City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Utah Cancer Specialists, Salt Lake City
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- Huntsman Cancer Institute, Salt Lake City
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- University of Utah Huntsman Cancer Institute, Salt Lake City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Huntsman Cancer Hospital at the University of Utah, Salt Lake City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- Farmington Health Center, Farmington · 15 mi lwen
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
Ap rekriteFaz 2
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- University of Utah - Huntsman Cancer Institute, Salt Lake City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, Salt Lake City
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Huntsman Cancer Institute, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Utah Cancer Specialists-Salt Lake City, Salt Lake City
- LDS Hospital, Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- START Center for Cancer Care - Mountain Region, Salt Lake City
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
Ap rekriteFaz 1 bonè
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Improving Care for Rural Patients With Solid Tumors
Ap rekrite
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
Ap rekriteFaz 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
SAVE Trial: SAfe Opioid Use Video Education
Ap rekrite
- University of Utah Huntsman Cancer Institute, Salt Lake City
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
Ap rekriteVolontè an sante akeyi
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Salt Lake City
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
Ap rekriteFaz 3
- Huntsman Cancer Institute at University of Utah, Salt Lake City
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- University of Utah- Huntsman Cancer Center, Salt Lake City
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
Ap rekrite
- University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences, Salt Lake City
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Salt Lake City
- Kansè Poumon ki pa ti selil31 etid
- Kansè (tout kalite)27 etid
- Kansè kolorektal22 etid
- Kansè poumon21 etid
- Melanom21 etid
- Myelom Miltip21 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Obèsite18 etid
- Leksemi mieloïd egi17 etid
- Ensifizyans kadyak17 etid
- Kansè pwostat15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.